GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
2.370
+0.130 (5.80%)
At close: Apr 1, 2025, 4:00 PM
2.140
-0.230 (-9.70%)
After-hours: Apr 1, 2025, 4:00 PM EDT

GT Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
8.577.1112.4547.926.28
Upgrade
Research & Development
5.86.478.819.590.49
Upgrade
Operating Expenses
14.3613.5821.2657.526.76
Upgrade
Operating Income
-14.36-13.58-21.26-57.52-6.76
Upgrade
Interest Expense
--0.21-0.01-0.72-3.32
Upgrade
Interest & Investment Income
0.40.780.290.04-
Upgrade
Other Non Operating Income (Expenses)
0.84.820.120.21-0.23
Upgrade
EBT Excluding Unusual Items
-13.16-8.19-20.85-57.98-10.31
Upgrade
Gain (Loss) on Sale of Investments
-0.05-0.03-0.03-
Upgrade
Legal Settlements
-----5.38
Upgrade
Other Unusual Items
-0.55---12.6
Upgrade
Pretax Income
-13.16-7.6-20.88-58.01-28.3
Upgrade
Earnings From Continuing Operations
-13.16-7.6-20.88-58.01-28.3
Upgrade
Net Income
-13.16-7.6-20.88-58.01-28.3
Upgrade
Net Income to Common
-13.16-7.6-20.88-58.01-28.3
Upgrade
Shares Outstanding (Basic)
21110
Upgrade
Shares Outstanding (Diluted)
21110
Upgrade
Shares Change (YoY)
40.78%26.87%13.18%542.06%29.59%
Upgrade
EPS (Basic)
-6.94-5.64-19.66-61.81-193.58
Upgrade
EPS (Diluted)
-6.94-5.64-19.66-61.81-193.58
Upgrade
Free Cash Flow
-12.9-8.85-15.22-15.61-7.26
Upgrade
Free Cash Flow Per Share
-6.80-6.57-14.32-16.63-49.68
Upgrade
EBITDA
-----6.76
Upgrade
D&A For EBITDA
----0
Upgrade
EBIT
-14.36-13.58-21.26-57.52-6.76
Upgrade
Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q